Pursuant to the resolution passed by shareholders on March 24, 2026, the company has consolidated its capital on a one-new-for-five-old basis. The name of the company has not been changed.

Effective at the opening on Friday, March 27, 2026, the common shares of XORTX Therapeutics Inc. will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a pharmaceutical and medicine manufacturing company.

Postconsolidation

Capitalization:  unlimited shares with no par value, of which 1,392,444 shares are issued and outstanding

Escrow:  nil shares subject to escrow

Transfer agent:  TSX Trust Company

Trading symbol:  XRTX (unchanged)

Cusip No.:  98420Q 40 5 (new)